14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment
30th September – 1st October 2014 • Congress Center Basel
SACHS Associates, London
Conference website
http://www.sachsforum.com/basel14/index.html
#Sachs14thBEF
Conference AGENDA
http://www.sachsforum.com/basel14/basel14-agenda.html
UPDATED on 8/4/2014 – SEE BELOW
http://www.sachsforum.com/basel14/Basel14-agenda.pdf
Sachs Associates is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.
Financial/Advisory Investors attending the 2014 Forum include: |
AbbVie Biotech Ventures, Inc. Advent Life Sciences Aescap Venture Management BV Aglaia Biomedical Ventures B.V. Amgen Ventures AmorChem apo Asset Management GmbH Aravis AG Aurum Ventures MKI Ltd. Bay City Capital BB Biotech Ventures Bergmann zur Hausen & Cie. GmbH BioMedPartners AG Boehringer Ingelheim Venture Fund Breslin AG Capricorn Venture Partners CD-Venture GmbH Cederberg GmbH CFP BioConnect AG Citi Group Creathor Ventures Cukierman & Co. Life Sciences Deutsche Bank AG Edison Investment Research Edmond de Rothschild Investment Partners Ernst & Young European Investment Fund Excellentia Gloabl Partners F. Hoffmann-La Roche AG Roche Venture Fund Forbion Capital Partners Fraser Finance Global Life Science Ventures HBM Partners AG HealthCap High-Tech Gruenderfonds Management GmbH IBB: Venture Capital Berlin Imperial Innovations Industrifonden JSB Partners LP Knoll Capital Management Kreos Capital Life Sciences Partners Lundbeckford Ventures LSP Medical Strategy GmbH MedVenture Partners GmbH MRL Ventures, Merck & Co., Inc. MS Ventures Nextech Invest Ltd NGN Captial Novartis Venture Fund Novo A/S NRW Bank Omega Funds Oriel Securities Limited Osprey Capital Partners Inc. Percipient Capital Pfizer Venture Investments Piper Jaffray Privateq Advisors AG Remaco AG RMI Partners Rosetta Capital Limited S.R.One, Limited SBS Investments Seroba Kernel Life Sciences Ltd. Siemens Technology Accelerator GmbH Silicon Valley Bank Sofinnova Partners Spinnovator – Ascenion GmbH Takeda Ventures, Inc. TEL Venture Capital, Inc Teralys Capital The Welcome Trust Torreya Partners (Europe) LLC TVM Capital Ventac Partners Vesalius Biocapital VI Partners Vinci Capital Visium Asset UK LLP Warwick Ventures Ltd Wellington Partners XOventure GmbH Yorkville Advisors, LLC Ysios Capital Partners |
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE
will cover the event for the Scientific Media
Dr. Lev-Ari will be in attendance on 9/30 and 10/1/2014 at
Congress Center Basel, Switzerland
by
SACHS Associates, London
http://www.sachsforum.com/basel14/Basel14-agenda.pdf
14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment
30th September – 1st October 2014 • Congress Center Basel
SACHS Associates, London
http://www.sachsforum.com/basel14/basel14-agenda.html
With an exciting new location, Basel, and expanded programme, we would like to invite you to join The 14th Annual Biotech in Europe Forum for Global Partnering & Investment. The Forum is recognised as the leading international stage for those interested in investing & partnering with the biotech and life science industry in Europe. There are numerous networking opportunities including a reception in the city on the evening of 30th, online 1-2-1 meeting system with meeting facilities and exhibition.
WE WOULD ALSO LIKE TO HIGHLIGHT:
- New Panels Added for 2014
– Drug Development and Manufacturing
– Pricing and Reimbursement.
Forum Agenda Now Online – click here to view
- Financial, Advisory and Investors Attending include:
AbbVie Biotech Ventures, Inc. • Advent Life Sciences • Aescap Venture Management BV • Aglaia Biomedical Ventures B.V. • Amgen Ventures
To view full list – click HERE
- Attendees:
AbbVie • Abingworth LLP • Actelion Pharmaceuticals, Ltd • ActoGeniX NV • Advent Life Sciences
To view full list – click HERE
- Confirmed Presenting Companies:
Actogenix NV • AFreeze GmbH • AIDD • Akron Molecules AG • AM-Pharma • AnaptysBio, Inc. • Anergis SA • APEIRON Biologics AG • APEPTICO • Arisgen SA • Asceneuron SA • B-Cell Design • BioCrea • BiolineRx • Biomay • Canbex Therapeutics Ltd. • CAP-CMV GmbH • Dana Farber Cancer Institute • Epigenomics AG • F-star Biotechnology Ltd. • Heptares Therapeutics Limited • Idera • InnoMedica Holding AG • Isarna Therapeutics • Karus Therapeutics • Lanthio Pharma • Lorus Therapeutics • MaxCyte, Inc. • Minoryx Therapeutics s.l. • Mucosis B.V. • Mymetics S.A. • NBE-Therapeutics • Neovacs • Novogen Ltd • Numab AG • Oncos Therapeutics • Opexa • Oryzon • OticPharma Ltd. • PCI Biotech • Pharmaco-Kinesis Corporation • Piqur Therapeutics AG • Re-pharm • Russian Pharmaceutical Technologies • Scancell Limited • Scil Proteins • Spectrum Pharmaceuticals • Synthena AG • Synthon Biopharma • Ugichem • VBI Vaccines • and more TBA.
FORUM PANELS WILL INCLUDE:
- Public Markets and M&A
- Future of Specialty Pharma
- Investment
- Partnering
- Early Stage Investment
- Scientific Collaborations
- Pricing and Reimbursement
- Drug Development and Manufacturing
- Israel
- Specific Therapeutic Panels:
– Autoimmune & Inflammatory
– CV & Metabolic Diseases
– Infectious Diseases
– Microbiome & Nutrition
– Neuroscience – Oncology
– Personalised Medicine & Diagnostics
– Platform Technologies & Novel Therapeutics
– Vaccines
Opportunities are available for you to join the event either as a delegate, presenter or exhibitor.
Please note we have limited presenting and exhibiting opportunities available.
♦ To enquire about Attending as a delegate click HERE.
♦ To enquire about Presenting click HERE.
♦ To enquire about Exhibiting click HERE.
We have reserved a number of complimentary places for accredited investors.
♦ To enquire about an accredited investor complimentary place click HERE
_______________________________
Please find information about special negotiated rates for events attendees at the local hotels at: https://hotel.basel.com/bpf2014/E
Confirmed Speakers & Chairs include:
Keynote Speakers:
- Anthony Rosenberg, Head of Global M&A and Licensing, Novartis Pharma AG
- Iris Welten, CEO, Basel Area
- Reinhard J. Ambros, Global Head, Novartis Venture Fund
Speakers:
- Alain Huriez, Venture Partner, Advent Life Sciences
- Andre Hoekema, Senior Vice President Corporate Development, Galapagos
- Andrew Macpherson, Professor Immunology, University of Bern
- Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.
- Barbara Dalton, VP Venture Capital, Pfizer Inc.
- Bernard Coulie, CEO, ActoGeniX NV
- Bernard Sixt, CEO, ImmunID
- Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
- Björn Odlander, Founding Partner, HealthCap
- Carlos Buesa, CEO, ORYZON
- Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
- Chris Britten, Head, Business Development, Sanofi Pasteur MSD
- Chris Maggos, Business Development, Alpine Institute for Drug Discovery
- Christina Takke, Partner, Forbion Capital Partners
- Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
- Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG
- Daniel Dornbusch, Chief Commercial Officer, Nodality, Inc.
- Dan J. Gelvin, Managing Director, Life Sciences, Aurum Ventures MKI Ltd.
- David Alderson, EU Practice Lead, Global Market Access Consulting, Evidera
- David Colpman, Head of Global Business Development, Shire
- Deborah Harland, General Partner, SR One
- Dirk Beher, CEO, ASCENEURON SA
- Prof. Edwin Constable, Head of Research, University of Basel
- Erik van den Berg, CEO, AM-Pharma B.V.
- Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics AG
- Dr Fintan Walton, Founder and CEO, PharmaVentures
- Florian Schödel, Owner, Philimmune, LLC
- Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
- Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH
- Genghis Lloyd-Harris, Partner, Abingworth LLP
To view the full list of speakers please click HERE
Presenting Opportunities
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.
Sponsorship and Exhibition
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages and exhibition packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please click the links at the top of the email or contact Mina Orda + 44 (0)203 463 4890
or by email: Mina Orda.
Warm Regards The Sachs Associates Team 27 Belsize Lane, London NW3 5AS Tel: +44 (0)203 463 4890 • Fax: +44 (0)207 691 7919 • www.SachsForum.com
To UNSUBSCRIBE click HERE
Follow us on Twitter @SachsAssociates Sponsored and supported by:
SOURCE
From: Ann Harris <ann@sachsforum.com>
Reply-To: <ann@sachsforum.com>
Date: Tue, 17 Jun 2014 15:08:59 +0100
To: <avivalev-ari@alum.berkeley.edu>
Subject: Agenda Now Online for the 14th Annual Biotech in Europe Investor Forum
About the 14th Annual Biotech in Europe Forum
The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.
The 14th Annual is held for the first time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.
Forum Panels will include:
- Public Markets and M&A
- Investment
- Partnering
- Early Stage Investment
- Regional Clusters
- Future of Specialty Pharma in Europe
- Israel
- Scientific Collaborations
- Pricing and Reimbursement
- Drug Discovery and Development
- Specific Therapeutic Panels:
- Autoimmune & Inflammatory
- CV & Metabolic Diseases
- Microbiome & Nutrition
- Infectious Diseases
- Neuroscience
- Oncology
- Personalised Medicine & Diagnostics
- Platform Technologies & Novel Therapeutics
- Vaccines
Confirmed Speakers include:
Keynote Speakers:
- Anthony Rosenberg, Head of Global M&A and Licensing, Novartis Pharma AG
- Iris Welten, CEO, Basel Area
- Reinhard J. Ambros, Global Head, Novartis Venture Fund
Speakers:
- Alain Huriez, Venture Partner, Advent Life Sciences
- Andre Hoekema, Senior Vice President Corporate Development, Galapagos
- Andrew Macpherson, Professor Immunology, University of Bern
- Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.
- Barbara Dalton, VP Venture Capital, Pfizer Inc.
- Bernard Coulie, CEO, ActoGeniX NV
- Bernard Sixt, CEO, ImmunID
- Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
- Björn Odlander, Founding Partner, HealthCap
- Carlos Buesa, CEO, ORYZON
- Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
- Chris Britten, Head, Business Development, Sanofi Pasteur MSD
- Chris Maggos, Business Development, Alpine Institute for Drug Discovery
- Christina Takke, Partner, Forbion Capital Partners
- Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
- Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG
- Daniel Dornbusch, Chief Commercial Officer, Nodality, Inc.
- David Colpman, Head of Global Business Development, Shire
- Deborah Harland, General Partner, SR One
- Dirk Beher, CEO, ASCENEURON SA
- Prof. Edwin Constable, Head of Research, University of Basel
- Erik van den Berg, CEO, AM-Pharma B.V.
- Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics AG
- Dr Fintan Walton, Founder and CEO, PharmaVentures
- Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
- Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund,
Boehringer Ingelheim GmbH - Genghis Lloyd-Harris, Partner, Abingworth LLP
- Graeme Martin, President and CEO, Takeda Research Investment
- Graham Kelly, Chief Executive Officer, Novogen Ltd
- Graziano Seghezzi, Partner, Sofinnova Partners
- Guillaume Vignon, Director Business Development Oncology – Global Business Development and Licensing, EMD Serono
- Hakan Goker, Investment Director, MS Ventures
- Hamza Suria, President & CEO, AnaptysBio, Inc.
- Jane Dancer, Chief Business Officer, F-star Biotechnology Ltd.
- Janet Hammond, Vice President, Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED), F.Hoffmann La Roche AG
- Janis Naeve, Managing Director, Amgen Ventures
- Jason Coloma, Global Head Venture & Innovation at Roche Partnering,
F.Hoffmann La Roche AG - Jeff Baxter, CEO, VBI Vaccines
- Jesse Schulman, CEO, Canbex Therapeutics Ltd.
- Johan Verbeeck, Senior Director of Partnership Management, Johnson & Johnson Innovation Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Johannes F. Zanzinger, Global Head, CardioMetabolic Business Development and Licensing,Boehringer Ingelheim Pharma GmbH & Co. KG
- John Gustofson, Senior Director, Venture and Early Stage Colaboration, AbbVie
- Kai Brüning, Senior Portfolio Manager, apo Asset Management GmbH
- Katya Smirnyagina, Partner, Capricorn Venture Partners
- Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
- Laurenz Kellenberger, CSO, Basilea
- Lorenza Castellon, Business Development Consultant, Suda Ltd.
- Lothar Steidler, Vice President Technology, ActoGeniX
- Lubor Gaal, Head of Europe, Strategic Transactions Group, BMS
- Luca Bolliger, VP and Group Licensing Director, RECORDATI S.A.
- Madhusudan V. Peshwa, Executive Vice President, Cellular Therapeutics, MaxCyte, Inc.
- Maina Bhaman, Director, Healthcare Ventures, Imperial Innovations
- Malcolm Weir, Co-Founder and Chief Executive Officer, Heptares Therapeutics
- Markus Ewert, EVP Business Development, GE Healthcare
- Matthieu Coutet, Managing Partner, Inserm Transfert Initiative
- Michael J. Hanewich, Managing Director, Healthcare and Life Science Venture Capital,
Silicon Valley Bank - Michael Shalmi, Senior Partner, Novo A/S
- N. Roa Movva, Novartis Distinguished Scientist, Executive Director,
DMP/NIBR/Novartis Pharma AG - Nicholas Franco, Executive Vice President & Chief Business Development Officer,
Actelion Pharmaceuticals, Ltd - O. Prem Das, Chief Research Business Development Officer and Heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana-Farber Cancer Institute (DFCI)
- Oliver Middendorp, Co-CEO & CBO, Numab AG
- Peter Burckhardt, Chief Executive Officer, EVA – the Basel life sciences start-up agency
- Philip A. Serlin, Chief Financial and Operating Officer, BioLineRx, Ltd.
- Philippe Calais, CEO, Isarna Therapeutics GmbH
- Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, MERCK KGaA / EMD
- Pierre Vandepapeliere, CMO, Neovacs
- Rainer Henning, CEO, Biomay AG
- Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH
- Rainer Strohmenger, General Partner, Wellington Partners
- Reid J. Leonard, Managing Director, MRL Ventures, Merck & Co., Inc.
- Richard Goodfellow, CEO, Scancell Holdings plc
- Robin Davison, Director, Healthcare, Edison Investment Research
- Søren Møller, Managing Investment Director, Novo Seeds
- Stefan Frings, Global Head, Oncology Immunology Therapeutic Area, Roche
- Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners
- Stewart Kay, Director Transactions, Worldwide Business Development, GSK
- Susan Hill, Director of Global Business Development, Alexion Pharma International Sarl
- Thomas Stockman, Director, Healthcare Investment Banking, Citi Group
- Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
- Tim Knotnerus, Director Business Development, Am-Pharma
- Tom Johnston, CEO, Mucosis B.V.
- Tom Kronbach, CEO, BioCrea
- Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
- Ulf Grawunder, CEO, NBE-Therapeutics Ltd
- Vincent Charlon, CEO, Anergis SA
- Vladimir Cmiljanovic, CEO, PIQUR Therapeutics AG
- Wilder Fulford, Principal, Torreya Partners (Europe) LLC
- And More TBA…
Presenting Opportunities
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.
Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.
The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners.
Sponsorship
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.
SOURCE
http://www.sachsforum.com/basel14/index.html
Editorials of event coverage via our Open Access Scientific Journal
http://pharmaceuticalintelligence.com
Scientific Journal Site Statistics
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
07/29/2013 217,356 1,138 1,389 705
12/01/2013 287,645 1,428 1,676 828
02/09/2014 325,039 1,665 1,793 892
03/05/2014 338,958 1,717 1,830 965
03/21/2014 347,667 1,750 1,838 974
03/31/2014 352,683 1,768 1,869 991
05/12/2014 373.696 1,878 1,944 1,035
06/18/2014 393,111 1,992 1,982 1,087
7/27/2014 418,570 2,098 2.050 1,124
9/2/2014 444,222 2,226 2,104 1,170
09/02/2014
444.222 Views
2,226 Articles
NATURE clicks 1,170
ncbi.nlm.nih.gov clicks 2,104
fda.gov clicks 198
cancer.gov clicks 162
Pre e-Pub e-Books Flyers
Series C: e-Books on Cancer & Oncology
Volume One: Cancer Biology and Genomics for Disease Diagnosis
Volume Two: Therapies in Cancer – Surgery, Radiation, Chemo and Immunotherapies
Series B: Frontiers in Genomics Research
Volume One: Genomics Orientations for Individualized Medicine
GENOMICS related articles in the JOURNAL
- Cardiovascular Pharmacogenomics – 134 articles
- Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics – 55 articles
- Nutrigenomics – 43 articles
- Pharmacogenomics – 88 articles
- Genomic Testing: Methodology for Diagnosis – 241 articles
- Personalized Medicine & Genomic Research – 390 articles
- Genome Biology – 421 articles
Leave a Reply